Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Waters Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector
Waters Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector


Waters Corporation (NYSE:WAT) today released the ACQUITY RDa™ Detector featuring SmartMS™, the company’s newest time-of-flight (TOF) mass spectrometer (MS) for small molecule analysis for

Dr. Katharine Knobil Named Agilent’s First Chief Medical Officer
Dr. Katharine Knobil Named Agilent’s First Chief Medical Officer


Agilent Technologies Inc. (NYSE: A), today announced that Dr. Katharine (Kate) Knobil is joining Agilent as the company’s chief medical officer (CMO). The chief medical officer at Agilent is a

PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC


PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec

Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection
Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection


Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. The CE-IVD mark is in

Neue Studie zeigt auf, dass mehr Auftragsforschungsinstitute Maßnahmen ergreifen, um dem dringenden Bedarf an schnelleren klinischen Studien gerecht zu werden
Neue Studie zeigt auf, dass mehr Auftragsforschungsinstitute Maßnahmen ergreifen, um dem dringenden Bedarf an schnelleren klinischen Studien gerecht zu werden


Auftragsforschungsinstitute machen bedeutende Fortschritte bei der Modernisierung und Verkürzung klinischer Studien, so die Ergebnisse der aktuellen Veeva Unified Clinical Operations Survey: Annual

Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia
Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia


Illumina, Inc.’s (NASDAQ: ILMN) NextSeq™ 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeq™Dx which was approved previously

PerkinElmer Prices Offering of Senior Notes: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer Prices Offering of Senior Notes


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it has priced an offering of $400.0 million aggregate principal amount of 2.550%

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, Executive Vice President, Global Supply, at the

New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials
New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials


Contract research organizations (CROs) are making significant advancements to modernize and speed clinical trials, according to the latest Veeva Unified Clinical Operations Survey: Annual CRO

New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials
New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials


Contract research organizations (CROs) are making significant advancements to modernize and speed clinical trials, according to the latest Veeva Unified Clinical Operations Survey: Annual CRO

U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancerhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer


The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA® (lorlatinib), expanding the indication to include first-line

Agilent Technologies Announces Pricing of $850 Million of Senior Notes
Agilent Technologies Announces Pricing of $850 Million of Senior Notes


Agilent Technologies, Inc. (NYSE: A) today announced the pricing of an underwritten, registered public offering of a series of its senior notes in an aggregate principal amount of $850 million. The

Humana and the University of Houston Announce New Value-based Care Specialization Program: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana and the University of Houston Announce New Value-based Care Specialization Program


Today, Humana (NYSE: HUM) and the University of Houston announced the launch of a Value-based Care Specialization online program to support providers, academia and other business and industry

Agilent Technologies Announces Proposed Offering of Senior Notes
Agilent Technologies Announces Proposed Offering of Senior Notes


Agilent Technologies Inc. (NYSE:A) today announced it is offering, subject to market and other conditions, a series of senior notes under an automatic shelf registration statement on file with the

Veeva Announces Fourth Quarter and Fiscal Year 2021 Results
Veeva Announces Fourth Quarter and Fiscal Year 2021 Results


Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fourth quarter and fiscal year ended January

Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics
Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics


Agilent Technologies Inc. (NYSE: A), today announced it has entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of

Agilent Announces Darlene Solomon Award Presented to University of Geneva Scientist Noemi Jiménez-Rojo
Agilent Announces Darlene Solomon Award Presented to University of Geneva Scientist Noemi Jiménez-Rojo


Agilent Technologies Inc. (NYSE: A) today announced that the recipient of the 2021 Darlene Solomon Award is Noemi Jiménez-Rojo, a postdoctoral fellow studying membrane biology, lipid diversity, and

Quidel Receives Emergency Use Authorization for QuickVue® At-Home COVID-19 Test
Quidel Receives Emergency Use Authorization for QuickVue® At-Home COVID-19 Test


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has

PerkinElmer to Present at Barclays Global Healthcare Conference: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer to Present at Barclays Global Healthcare Conference


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Barclays Global Healthcare Conference on

European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Olderhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older


Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine

EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiencyhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency


Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for

Humana Military Names Alefiyah Mesiwala, M.D., Chief Medical Officer
Humana Military Names Alefiyah Mesiwala, M.D., Chief Medical Officer


Humana Military, a wholly owned subsidiary of Humana Inc. (NYSE: HUM), announced today the appointment of Alefiyah Mesiwala, M.D., MPH, as Humana Military’s new Chief Medical Officer. Effective

Mercy and Humana Team Up to Expand Access to Virtual Health Services and Coordinated Care: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Mercy and Humana Team Up to Expand Access to Virtual Health Services and Coordinated Care


Missouri-based Mercy and leading health and well-being company Humana Inc. (NYSE: HUM) have signed an agreement to expand patient access to virtual health resources as part of a broader, joint

Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variantshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine